Podcasts about sequenom

The healthcare industry is facing a lot of challenges, like physician burnout, the high cost of care, a lack of insurance coverage, staffing problems, and a lack of adequate interactions between patients and providers, just to name a few. With the loads of technology and applications available, many providers still use fax machines as a mode of communication, making patient access to specialty care difficult and increasing the risk of compromising security. How can this problem be eradicated to increase first response, improve care transitions, and speed up the adoption of e-consults?In this new episode of Highway to Health, a podcast by MarketScale, host David Kemp chatted with Brooke LeVasseur, the CEO of AristaMD, the best person to provide insight into these questions and talk about the delivery of e-consults for patients and providers.At the start of the episode, Kemp asked LeVasseur about the habits she has adopted to maintain her physical and mental stability:"For me, and I've struggled with this my whole life, every year I recommit to improving my sleep. Sleep is like the number one building block, and that's an ongoing struggle for me, but I try to setup good routines for myself so that I'm getting solid, uninterrupted sleep. For stress relief, I'm really into athletic activities. I try to be outside, take walks, and my whole family is into surfing... I can't get started until I get some sweat on, and that helps me stay sane and focused—it's a lot of great benefit," LeVasseur said.Kemp and LeVasseur's conversation included the following:• Health equity• E-consults: Other technologies patients can use other than a FaceTime experience• What goes into care coordination and communication between PCPs and specialists• Who has the biggest lever that could be used to speed up the adoption of digital platforms that improve outcomes. "I think the technologies that have been effective in helping that problem are those that let physicians do what they are meant to do, which is treat patients and get more face-to-face patient time. Arista is focused on how we can get providers to not only do what they are trained to do but really to let everyone in the healthcare system operate at the top of their license, and sometimes you can best do that by giving them technology tools so that they are handling the most complex, acute cases that are appropriate for their licensure," LeVasseur explained."Health equity really requires everyone to have access to affordable care and that they can get to that care in a timely fashion. If you are far away from providers, it's a challenge for anyone living in those remote districts, but surprisingly, folks have huge access problems that lead to inequity in urban settings. Sometimes the barrier isn't your location; it might be your health insurance. We see tons of Medicaid patients struggling to get care because specialists won't see Medicaid patients," she added.Brooke LeVasseur is the CEO of AristaMD and has 20 years of leadership experience launching new, innovative healthcare products and solutions for payers and providers, including software and e-consult solutions. Throughout her career, LeVasseur has worked with numerous startups in a variety of capacities, including corporate and commercial strategy, marketing, and new business creation. She brings a wealth of experience drawn from executive roles at Thomson Reuters, Veracyte, and Sequenom, as well as an array of consultant roles at industry-leading investment and healthcare companies such as Kleiner Perkins Caufield & Byers, Versant Ventures, Illumina, Cypher Genomics, and GRAIL. She has led teams to successfully commercialize new, innovative healthcare tools and gain widespread clinician adoption and reimbursement. She holds a degree in English from Stanford University.

The healthcare industry is facing a lot of challenges, like physician burnout, the high cost of care, a lack of insurance coverage, staffing problems, and a lack of adequate interactions between patients and providers, just to name a few. With the loads of technology and applications available, many providers still use fax machines as a mode of communication, making patient access to specialty care difficult and increasing the risk of compromising security. How can this problem be eradicated to increase first response, improve care transitions, and speed up the adoption of e-consults?In this new episode of Highway to Health, a podcast by MarketScale, host David Kemp chatted with Brooke LeVasseur, the CEO of AristaMD, the best person to provide insight into these questions and talk about the delivery of e-consults for patients and providers.At the start of the episode, Kemp asked LeVasseur about the habits she has adopted to maintain her physical and mental stability:"For me, and I've struggled with this my whole life, every year I recommit to improving my sleep. Sleep is like the number one building block, and that's an ongoing struggle for me, but I try to setup good routines for myself so that I'm getting solid, uninterrupted sleep. For stress relief, I'm really into athletic activities. I try to be outside, take walks, and my whole family is into surfing... I can't get started until I get some sweat on, and that helps me stay sane and focused—it's a lot of great benefit," LeVasseur said.Kemp and LeVasseur's conversation included the following:• Health equity• E-consults: Other technologies patients can use other than a FaceTime experience• What goes into care coordination and communication between PCPs and specialists• Who has the biggest lever that could be used to speed up the adoption of digital platforms that improve outcomes. "I think the technologies that have been effective in helping that problem are those that let physicians do what they are meant to do, which is treat patients and get more face-to-face patient time. Arista is focused on how we can get providers to not only do what they are trained to do but really to let everyone in the healthcare system operate at the top of their license, and sometimes you can best do that by giving them technology tools so that they are handling the most complex, acute cases that are appropriate for their licensure," LeVasseur explained."Health equity really requires everyone to have access to affordable care and that they can get to that care in a timely fashion. If you are far away from providers, it's a challenge for anyone living in those remote districts, but surprisingly, folks have huge access problems that lead to inequity in urban settings. Sometimes the barrier isn't your location; it might be your health insurance. We see tons of Medicaid patients struggling to get care because specialists won't see Medicaid patients," she added.Brooke LeVasseur is the CEO of AristaMD and has 20 years of leadership experience launching new, innovative healthcare products and solutions for payers and providers, including software and e-consult solutions. Throughout her career, LeVasseur has worked with numerous startups in a variety of capacities, including corporate and commercial strategy, marketing, and new business creation. She brings a wealth of experience drawn from executive roles at Thomson Reuters, Veracyte, and Sequenom, as well as an array of consultant roles at industry-leading investment and healthcare companies such as Kleiner Perkins Caufield & Byers, Versant Ventures, Illumina, Cypher Genomics, and GRAIL. She has led teams to successfully commercialize new, innovative healthcare tools and gain widespread clinician adoption and reimbursement. She holds a degree in English from Stanford University.

Nola Masterson was the first female biotech analyst on Wall Street, and since then, she's been empowering women to step up and follow their passions and talents whether that's in a job or on a board. Her self-powered career, at a time when it was much tougher for women in business, is a model for all women to follow.In this episode you'll hear:How and why to follow your passion in life and work.Why women are short-changed when it comes to funding.How you can support women-owned companies.Ways to balance work and life.How to take control of your financial future. If you enjoyed this episode and it inspired you in some way, we'd love to hear about it and know your biggest takeaway. Take a screenshot of yourself listening to the episode on your device, post it to your Instagram Stories, and tag me @debbiegisonni on Instagram and @debbiegisonnipage on Facebook. You can also watch this episode on YouTube at: https://youtu.be/qcKI39ozc7E About Nola:Nola Masterson has had an extensive career in venture capital investments and Board of Directors work. She sits on early-stage company boards and public traded company boards. She coaches aspirational board candidates and is enthusiastic about getting diverse representation around the board table. As a lead investor in Portfolia Femtech Fund now she helps educate and support women investors to be comfortable investing at the angel level in companies that have products and services for women's health and wellness from birth to menopause. She was a trailblazer for women in corporate sales management at Millipore and Ames Company, and the first biotechnology analyst on Wall Street. She co-founder a DNA analysis company, Sequenom, that went public in 2000. She is co-chair of the Women Corporate Directors chapter in San Francisco. Her work with Boardwise includes coaching and consulting with boards and individual board members. She has been honored as a pioneer in biotechnology by Fordham University. She is a published author and dynamic public speaker.Her hobbies include horse-back riding and oil painting.Connect with Nola:Website: https://www.portfolia.coLinkedIn: https://www.linkedin.com/in/nola-e-masterson-b6711/Connect with Debbie:Website – Books, Online Courses, Podcasts: https://www.selfpowernow.comFacebook: https://www.facebook.com/DebbieGisonniPage/IG: https://www.instagram.com/debbiegisonni/LinkedIn: https://www.linkedin.com/in/dgisonni/YouTube: https://www.youtube.com/user/DebbieGisonni

In this episode, Hall welcomes Donna Hamlin, CEO, & Nola Masterson, Partner at Boardwise. Boardwise provides companies and executives with the highest quality solutions, tools, education, independent evaluations, research, breaking news, and advisory support in corporate governance and management available for governance needs around the globe. They work with all forms of companies and organizations, including private and public corporations and associations, non-profit organizations and executives, and teams with a passion for better governance practices. Donna is the founder and board chair of Hamlin Harkins, Ltd., a 39-year-old global management consultancy providing services in strategy, business development and performance improvement to executive teams across diverse industries. Donna helps board directors and executives discover and develop personal competencies which ensure sustainable success for themselves and their organizations. She is certified in global governance by Harvard University. A published author, she writes articles about human performance and change management. Donna currently serves on the private company boards of Daily Pay, Inc., AussieWeb, Inc., the Themyscira Institute, and on the advisory boards for Fresh Bellies Inc., Joylux Inc., and Lead Women in Malaysia. She previously served on the board of Interhealth USA, and the compensation committees for publicly-listed companies, Trident Microsystems and Asyst Technologies.   Nola has had a long career in venture capital investments and board of directors’ work. She sits on early-stage company boards and publicly traded company boards. Nola coaches aspirational board candidates and is passionate about getting diverse representation around the board table. As a lead investor in Portfolia Femtech Fund, she helps educate and support women investors to be comfortable investing at the angel level in companies that have products and services for women's health and wellness, from birth to menopause. She was a trailblazer for women in corporate sales management at Millipore and Ames Company, and the first biotechnology analyst on Wall Street. She is the co-founder of a DNA analysis company, Sequenom, which went public in 2000.  Nola also teaches at the graduate level at the University of San Francisco and is the co-chair of the Women Corporate Directors chapter in SF. Her work with Boardwise includes coaching and consulting with boards and individual board members. She has been honored as a pioneer by Fordham University and is a published author and dynamic public speaker. Donna and Nola discuss their investment theses, advise startups and investors, and share some of the challenges they face. You can visit Boardwise at , via LinkedIn at , and via Twitter at .   Donna can be contacted via email at . Nola can be contacted via email at , and via LinkedIn at .  Music courtesy of .

Front Range Biosciences with VP of R&D Dr. Reggie Gaudino today on Concierge For Better Living With Doc Rob only on Cannabis Radio. Dr. Gaudino oversees the cannabis genetics and scientific research division for Front Range Biosciences. Formerly the President at Steep Hill, the acquisition of Reggie and his team have significantly advanced FRB’s breeding program, resulting in additional unique and advantaged cannabis and hemp varieties. Dr. Gaudino believes that by using science and technology to help customers succeed and increase profits, FRB can build stronger relationships and be a better partner for customers. Dr. Gaudino has also served as a genetics researcher with 18-years of intellectual property experience in patent writing, management, and prosecution in fields as diverse as software and telecommunications to biotechnology and molecular genetics. Research from Dr. Gaudino has been peer-reviewed and published, leading to important new discoveries in the cannabis industry. As an internationally recognized leader in the field of cannabis genetics, Dr. Gaudino has served as a patent agent at Sequenom, Inc., managed IP-based acquisitions for the Vortice Research Group, worked at four law firms focused on biotechnology, and an advisor to multiple portfolio investment companies. Dr. Gaudino received his B.S. in Molecular Biology and Ph.D. in Molecular Genetics from the State University of New York at Buffalo and conducted four years of post-doctoral research at Washington University in St. Louis.

Chris and Neal discuss the promise of at-home diagnostic testing with guest Dirk van den Boom, CEO, and Co-Founder of Juno Diagnostics. Dirk furthermore shares the next phase in bringing high-value medical information to patients and consumers, empowering personal health, and improving the patient-physician relationship. Dirk is a healthcare executive with over twenty years in diagnostics and genetic testing. Previously as CEO of Sequenom during the human genome sequencing period, he lead Sequenom’s acquisition by LabCorp for ~$400M.

Today's show was recorded July 1st, the first day that Vermont’s GMO labeling law went into effect. Just how big a win was this for the anti-GMO crowd, we ask our two commentators, Nathan Pearson and Laura Hercher. They have a surprisingly optimistic take, suggesting that the GMO labeling could become a positive marketing tool.

It’s a non-decision with big implications. On Monday, the Supreme Court turned down an appeal by Sequenom in their patent case with Ariosa. The rebuff by the highest court kills Sequenom’s prenatal screening test patent for good.

CHI president Phillips Kuhl and Sequenom CMO Daniel Grosu discuss how Sequenom is applying new technology to address the next sets of clinical questions for non-invasive prenatal testing. To learn more, please visit http://www.MolecularDXEurope.com/

Paul Browne and I discuss two companies that did some foolish things (KV and Sequenom), the link between terbuataline and autism (not so much), how nulliparous inductions don’t increase cesareans (if you make a bad enough study), and a few other odds and ends.   Academic OB/GYN Podcast Episode 32 – Journals for February and […]

Background: Restless legs syndrome (RLS) is associated with common variants in three intronic and intergenic regions in MEIS1, BTBD9, and MAP2K5/LBXCOR1 on chromosomes 2p, 6p and 15q.Methods: Our study investigated these variants in 649 RLS patients and 1230 controls from the Czech Republic (290 cases and 450 controls), Austria (269 cases and 611 controls) and Finland (90 cases and 169 controls). Ten single nucleotide polymorphisms (SNPs) within the three genomic regions were selected according to the results of previous genome-wide scans. Samples were genotyped using Sequenom platforms.Results: We replicated associations for all loci in the combined samples set (rs2300478 in MEIS1, p = 1.26×10-5, odds ratio (OR) = 1.47, rs3923809 in BTBD9, p = 4.11×10-5, OR = 1.58 and rs6494696 in MAP2K5/LBXCOR1, p = 0.04764, OR = 1.27). Analysing only familial cases against all controls, all three loci were significantly associated. Using sporadic cases only, we could confirm the association only with BTBD9.Conclusion: Our study shows that variants in these three loci confer consistent disease risks in patients of European descent. Among the known loci, BTBD9 seems to be the most consistent in its effect on RLS across populations and is also most independent of familial clustering.